The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 569 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties.

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2023. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cancer monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

   

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction

2.2. Cancer monoclonal antibody deals over the years

2.3. Most active cancer monoclonal antibody dealmakers

2.4. Cancer monoclonal antibody deals by deal type

2.5. Cancer monoclonal antibody deals by therapy area

2.6. Cancer monoclonal antibody deals by industry sector

2.7. Deal terms for cancer monoclonal antibody deals

2.7.1 Cancer monoclonal antibody deals headline values

2.7.2 Cancer monoclonal antibody deal upfront payments

2.7.3 Cancer monoclonal antibody deal milestone payments

2.7.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading cancer monoclonal antibody deals

3.1. Introduction

3.2. Top cancer monoclonal antibody deals by value

Chapter 4 - Most active cancer monoclonal antibody dealmakers

4.1. Introduction

4.2. Most active cancer monoclonal antibody dealmakers

4.3. Most active cancer monoclonal antibody deals company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

5.1. Introduction

5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

Deal directory

Deal directory - Cancer monoclonal antibody deals by company A-Z

Deal directory - Cancer monoclonal antibody deals by deal type

Deal directory - Cancer monoclonal antibody deals by therapy area

Companies Mentioned

• 3SBio
• Abpro
• Ambrx
• Amgen
• ATP
• Bayer
• Binex
• Biomm
• Cipla
• Dako
• Eisai
• I-mab
• IMV
• Ipsen
• IRBM
• Kymab
• Lonza
• Merus
• MSD
• Numab
• Roche
• Taiho
• UCB
• VIB
• Wilex
• Xoma
• Cilag AG
• NKMax America
• Viela Bio
• Essex Bio-Technology

For more information about this report visit https://www.researchandmarkets.com/r/2fbd9z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231115558538/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.